Showing 3241-3250 of 20413 results for "".
Optimizing Monitoring after Ide-cel in RRMM: What the Evidence Shows
https://reachmd.com/programs/Audioabstracts/monitoring-ide-cel-rrmm/48730/This is a non-certified educational series produced and controlled by ReachMD. As CAR T-cell therapy becomes more widely used in multiple myeloma, understanding when toxicities occur is critical to balancing safety and access. Hear from Dr. Mimi Maeusli as she reviews new clinical and real-world finDiuretic Response in the ICU: A Practical Predictor of Renal Trajectory
https://reachmd.com/programs/clinicians-roundtable/diuretic-response-in-the-icu-a-practical-predictor-of-renal-trajectory/37219/Identifying Hidden Risk: Metabolomic Patterns in Childhood Obesity
https://reachmd.com/programs/clinicians-roundtable/identifying-hidden-risk-metabolomic-patterns-in-childhood-obesity/39654/Vutrisiran for ATTR-CM: Impacts on Functional Capacity and Quality of Life
https://reachmd.com/programs/on-the-frontlines-of-attr-cm/vutrisiran-for-attr-cm-impacts-on-functional-capacity-and-quality-of-life/39314/When evaluating treatment options for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), functional capacity and quality of life are crucial to take into account. That's why the HELIOS-B trial, published in the Journal of the American College of Cardiology in May 2025, assessed tThe Future of PI3K Inhibition in HR+/HER2- Breast Cancer
https://reachmd.com/programs/cme/The-Future-of-PI3K-Inhibition-in-HR-HER2-Breast-Cancer/37339/Join Drs. Jhaveri and Kalinsky and get up to speed on the latest data on PI3K-directed therapies and their role in the treatment paradigm for HR+, HER2- mBC.Double Take: Pivotal Data Evaluating PI3K Inhibitor/Endocrine Therapy Regimens in mBC
https://reachmd.com/programs/cme/Double-Take-Pivotal-Data-Evaluating-PI3K-Inhibitor-Endocrine-Therapy-Regimens-in-mBC/37333/Join Drs. Jhaveri and Kalinsky and get up to speed on the latest data on PI3K-directed therapies and their role in the treatment paradigm for HR+, HER2- mBC.PI3K Pathway Inhibition in HR+/HER2- mBC: Mechanistic Insights
https://reachmd.com/programs/cme/PI3K-Pathway-inhibition-in-HR-HER2-mBC-Mechanistic-Insights/37329/Join Drs. Jhaveri and Kalinsky and get up to speed on the latest data on PI3K-directed therapies and their role in the treatment paradigm for HR+, HER2- mBC.Evaluating Digital CBT for Sickle Cell Disease: Insights From the CaRISMA Trial
https://reachmd.com/programs/project-oncology/evaluating-digital-cbt-for-sickle-cell-disease-insights-from-the-carisma-trial/36526/Clinical Insights Into T-Cell Immunity After Pediatric COVID-19 mRNA Vaccination
https://reachmd.com/programs/clinicians-roundtable/clinical-insights-into-t-cell-immunity-after-pediatric-covid-19-mrna-vaccination/37133/Pictorial Eczema Education Shows Promise for Improving Patients’ Quality of Life
https://reachmd.com/programs/dermconsult/pictorial-eczema-education-shows-promise-for-improving-patients-quality-of-life/36438/